Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

TARGETED THERAPY

A trojan horse to target spliceosome mutant cells

Nature Reviews Cancer volume 22, page 257 (2022)Cite this article

Subjects

Spliceosomal mutations occur frequently in several cancer types. However, therapeutic drugs targeting mutant spliceosomal proteins are unavailable. In this study, North, Benbarche et al. engineered synthetic introns that were spliced specifically in cancer cells expressing the mutant spliceosome factor SF3B1. This led to expression of herpes simplex virus-thymidine kinase (HSV-TK) and vulnerability of cancer cells to treatment with the antiviral drug ganciclovir (GCV).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Cancer http://www.nature.com/nrc/

    Ulrike Harjes

Authors
  1. Ulrike Harjes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrike Harjes.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harjes, U. A trojan horse to target spliceosome mutant cells. Nat Rev Cancer 22, 257 (2022). https://doi.org/10.1038/s41568-022-00472-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41568-022-00472-3

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer